| An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (NCT02038569) | LEO Pharma | 2014-01-01 |
| Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (NCT02004574) | Jooheung Lee | 2013-10-01 |
| Blue Light for Treating Psoriasis Vulgaris (NCT02004847) | Philips Electronics Nederland BV | 2013-09-01 |
| A Vasoconstriction Study With LEO 90100 (NCT01946386) | LEO Pharma | 2013-09-01 |
| Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100 (NCT01935869) | LEO Pharma | 2013-08-01 |
| Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients (NCT01936337) | Delenex Therapeutics AG | 2013-08-01 |
| An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life (NCT01982552) | LEO Pharma | 2013-07-01 |
| LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (NCT01866163) | LEO Pharma | 2013-06-01 |
| An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris (NCT01837576) | LEO Pharma | 2013-04-01 |
| Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis (NCT05488990) | Lipidor AB | 2013-03-25 |
| Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris (NCT01743118) | Circassia Limited | 2013-03-01 |
| Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment (NCT01735864) | Chang Gung Memorial Hospital | 2012-11-01 |
| The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients (NCT01651559) | Ahava Dead Sea Laboratories | 2012-11-01 |
| Mechanistic Study of Indigo Naturalis in Treating Psoriasis (NCT02088281) | Chang Gung Memorial Hospital | 2012-11-01 |
| Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation (NCT01707368) | LEO Pharma | 2012-10-01 |
| Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study (NCT01702324) | Fortuderm Ltd. | 2012-10-01 |
| The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (NCT01768013) | LEO Pharma | 2012-07-01 |
| A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris (NCT01607853) | LEO Pharma | 2012-06-01 |
| Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris (NCT01600222) | LEO Pharma | 2012-05-01 |
| LEO 90100 in the Treatment of Psoriasis Vulgaris (NCT01536938) | LEO Pharma | 2012-05-01 |
| LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (NCT01536886) | LEO Pharma | 2012-05-01 |
| A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris (NCT01580488) | LEO Pharma | 2012-04-01 |
| Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis (NCT03069144) | Haus Bioceuticals | 2012-01-06 |
| Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris (NCT01465282) | Creabilis SA | 2011-12-01 |
| An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris (NCT01466478) | LEO Pharma | 2011-11-01 |
| Incretin Effect in Patients With Psoriasis and Controls (NCT06064084) | University Hospital, Gentofte, Copenhagen | 2011-09-11 |
| Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 (NCT01443338) | Ministry of Health, China | 2011-09-01 |
| A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris (NCT01347255) | LEO Pharma | 2011-05-01 |
| Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris (NCT01320774) | LEO Pharma | 2011-04-01 |
| Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency (NCT01339741) | Chulalongkorn University | 2011-03-01 |
| A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris (NCT01297166) | LEO Pharma | 2011-02-01 |
| Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris (NCT01229098) | LEO Pharma | 2010-10-01 |
| LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) (NCT01188928) | LEO Pharma | 2010-09-01 |
| A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris (NCT01116895) | LEO Pharma | 2010-05-01 |
| A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis (NCT01105286) | LEO Pharma | 2010-04-01 |
| A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris (NCT01268527) | Eisai Limited | 2010-03-15 |
| Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT01072383) | Biotest | 2010-02-01 |
| A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris (NCT01043224) | LEO Pharma | 2010-01-01 |
| Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis (NCT01022502) | Yin-ku Lin | 2009-11-01 |
| A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas (NCT01007591) | LEO Pharma | 2009-10-01 |
| Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (NCT00817219) | LEO Pharma | 2009-07-01 |
| Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis (NCT00924950) | University of California, San Francisco | 2009-06-01 |
| A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (NCT00875277) | LEO Pharma | 2009-04-01 |
| LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects (NCT00833872) | LEO Pharma | 2009-01-01 |
| A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (NCT00845481) | LEO Pharma | 2009-01-01 |
| Use of Botulinum Toxin to Treat Psoriasis (NCT00816517) | University of Minnesota | 2009-01-01 |
| Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris (NCT00764751) | LEO Pharma | 2008-09-01 |
| Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds (NCT00691002) | LEO Pharma | 2008-05-01 |
| Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds (NCT00704262) | LEO Pharma | 2008-05-01 |
| Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (NCT00670241) | LEO Pharma | 2008-04-01 |
| Safety and Efficacy of Combining nbUVB to Etanercept in Patients (NCT00640393) | Innovaderm Research Inc. | 2008-04-01 |
| Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol (NCT00678756) | Technische Universität Dresden | 2008-03-01 |
| Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds (NCT00640822) | LEO Pharma | 2008-02-01 |
| A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis (NCT00593177) | Manhattan Pharmaceuticals | 2007-10-01 |
| Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris (NCT00263718) | LEO Pharma | 2005-12-01 |
| Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris (NCT00248456) | LEO Pharma | 2005-10-01 |
| Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris (NCT00365625) | Johann Wolfgang Goethe University Hospital | 2005-07-01 |
| Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris (NCT00216892) | LEO Pharma | 2005-04-01 |
| Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test (NCT00236171) | Technische Universität Dresden | 2004-09-01 |
| Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris. (NCT00220025) | Mary Sullivan-Whalen | 1999-06-01 |
| Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris (NCT00287547) | Bristol-Myers Squibb | 1997-03-01 |
| A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris (NCT00277225) | Bristol-Myers Squibb | 1995-11-01 |
| Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris (NCT00306878) | Bristol-Myers Squibb | 1995-08-01 |